Case Report
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. May 16, 2023; 11(14): 3267-3274
Published online May 16, 2023. doi: 10.12998/wjcc.v11.i14.3267
Immune checkpoint inhibitor therapy-induced autoimmune polyendocrine syndrome type II and Crohn’s disease: A case report
Mei-Juan Gao, Yan Xu, Wen-Bo Wang
Mei-Juan Gao, Yan Xu, Wen-Bo Wang, Department of Endocrinology, Peking University Shougang Hospital, Beijing 100041, China
Author contributions: Gao MJ and Xu Y provided clinical care for the patient; Gao MJ wrote the manuscript; Wang WB was the attending consultant, and he reviewed the final draft of the manuscript; All authors contributed to the writing, editing, and review of the manuscript.
Informed consent statement: The patient and his family signed a letter of consent to the summary of the case report and the publication of the informed notice.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read CARE Checklist (2016), and the manuscript was prepared and revised according to CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Corresponding author: Mei-Juan Gao, MD, Chief Physician, Department of Endocrinology, Peking University Shougang Hospital, No. 9 Jinyuanzhuang Road, Beijing 100041, China.
Received: December 4, 2022
Peer-review started: December 4, 2022
First decision: February 7, 2023
Revised: February 17, 2023
Accepted: April 6, 2023
Article in press: April 6, 2023
Published online: May 16, 2023
Core Tip

Core Tip: We report a rare case of multi-system damage induced by cancer therapy with protein 1 ligand inhibitor teriprizumab. A man with squamous cell carcinoma of oropharynx on a combination regimen of teriprizumab, docetaxel, and cisplatin developed autoimmune polyendocrine syndrome type II (APS-2) including thyroiditis and type 1 diabetes mellitus (T1DM) and Crohn’s disease (CD). This case report highlights the possibility of chronic immune toxicities and the long-term implications of cancer immunotherapy. To the best of our knowledge, this is the first reported case of concurrent atypical APS-2 (including T1DM and thyrotoxicosis) and CD in a patient receiving immunotherapy for metastatic nasopharyngeal carcinoma.